| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ff40e5f9fe4a871b3c1ef0cdccfa05a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 |
| filingDate |
2020-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da3b855b978cab6d492db4b71a75fe91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c4fb359a9a1a4c92005b9c90e493424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cef61edc01470010e5c5521b6c53c1c |
| publicationDate |
2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021058866-A1 |
| titleOfInvention |
Method for determining potency of therapeutic anti-clever-1 antibody |
| abstract |
A method for determining a potency of a therapeutic anti-Clever-1 antibody or fragment(s) thereof capable of binding to human Clever-1 by inhibition of a modified low-density lipoprotein uptake, wherein the inhibition of modified low-density lipoprotein uptake is an indication of biological activity of said anti-Clever-1 antibody or fragment(s) thereof. |
| priorityDate |
2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |